JP2010522699A5 - - Google Patents

Download PDF

Info

Publication number
JP2010522699A5
JP2010522699A5 JP2010500039A JP2010500039A JP2010522699A5 JP 2010522699 A5 JP2010522699 A5 JP 2010522699A5 JP 2010500039 A JP2010500039 A JP 2010500039A JP 2010500039 A JP2010500039 A JP 2010500039A JP 2010522699 A5 JP2010522699 A5 JP 2010522699A5
Authority
JP
Japan
Prior art keywords
scoliosis
opn
subject
expression
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010500039A
Other languages
English (en)
Japanese (ja)
Other versions
JP5426530B2 (ja
JP2010522699A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2008/000595 external-priority patent/WO2008119170A1/en
Publication of JP2010522699A publication Critical patent/JP2010522699A/ja
Publication of JP2010522699A5 publication Critical patent/JP2010522699A5/ja
Application granted granted Critical
Publication of JP5426530B2 publication Critical patent/JP5426530B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010500039A 2007-03-30 2008-03-31 脊柱側弯症の危険性の決定方法 Expired - Fee Related JP5426530B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US90940807P 2007-03-30 2007-03-30
US60/909,408 2007-03-30
US2557108P 2008-02-01 2008-02-01
US61/025,571 2008-02-01
PCT/CA2008/000595 WO2008119170A1 (en) 2007-03-30 2008-03-31 Method of determining risk of scoliosis

Publications (3)

Publication Number Publication Date
JP2010522699A JP2010522699A (ja) 2010-07-08
JP2010522699A5 true JP2010522699A5 (show.php) 2011-04-28
JP5426530B2 JP5426530B2 (ja) 2014-02-26

Family

ID=39807753

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010500039A Expired - Fee Related JP5426530B2 (ja) 2007-03-30 2008-03-31 脊柱側弯症の危険性の決定方法

Country Status (10)

Country Link
US (3) US20100075333A1 (show.php)
EP (1) EP2132568B1 (show.php)
JP (1) JP5426530B2 (show.php)
KR (1) KR101436578B1 (show.php)
CN (1) CN101680887B (show.php)
AU (1) AU2008234374B2 (show.php)
CA (1) CA2682114C (show.php)
IL (1) IL201186A (show.php)
MX (1) MX2009010400A (show.php)
WO (1) WO2008119170A1 (show.php)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9029094B2 (en) * 2010-10-04 2015-05-12 Chu Sainte-Justine Biomechanical-based methods of diagnosing scoliosis
DE102012102338A1 (de) 2012-03-20 2013-09-26 Hauni Maschinenbau Ag Messanordnung zum Messen von in Strangmaschinen der Tabak verarbeitenden Industrie hergestellten und geförderten Strängen
US20150038511A1 (en) 2012-08-09 2015-02-05 Celgene Corporation Treatment of immune-related and inflammatory diseases
WO2014025958A2 (en) 2012-08-09 2014-02-13 Celgene Corporation Treatment of immune-related and inflammatory diseases
EP3513808A1 (en) 2013-06-17 2019-07-24 CHU Sainte-Justine A method of increasing gipcr signalization in the cells of a scoliotic subject
WO2014201557A1 (en) 2013-06-17 2014-12-24 Chu Ste-Justine Gi protein phosphorylation as marker for scoliosis and scoliosis progression, methods of increasing gipcr signaling in scoliotic subjects
AU2014284078A1 (en) 2013-06-17 2016-01-07 Chu Sainte-Justine New markers for severe progression of idiopathic scoliosis and uses thereof to stratify scoliotic patients and predict the risk of developing scoliosis
EP3647789A1 (en) * 2013-09-09 2020-05-06 Chu Sainte-Justine New marker for the classification, diagnosis and treatment of scoliosis
US10245266B2 (en) 2014-05-19 2019-04-02 Celgene Corporation 3-(4-((4-morpholinomethyl-benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione for the treatment of systemic lupus erythematosus
CN106310610A (zh) * 2016-10-21 2017-01-11 上海交通大学医学院附属新华医院 一种脊柱侧凸特定运动疗法
CN106841593B (zh) * 2017-03-24 2018-08-17 北京致成生物医学科技有限公司 Lacc1和fhl2基因在制备脊柱侧弯检测产品中的应用
CN111638329B (zh) * 2020-06-09 2021-06-01 南方医科大学 一种用于检测布鲁氏菌病elispot检测试剂盒及其应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
SE9101642D0 (sv) * 1991-05-30 1991-05-30 Kabi Pharmacia Ab Phospholipids
WO1996006622A1 (en) 1991-07-03 1996-03-07 Hyal Pharmaceutical Corporation Hyaluronic acid and derivatives for modulation of cellular activity
EP0767380A1 (de) * 1993-06-22 1997-04-09 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Verfahren zur Diagnose und Analyse von Zervixkarzinomen
US5858709A (en) * 1996-10-15 1999-01-12 Smithkline Beecham P.L.C. Fibronectin binding protein B compounds
US20020160970A1 (en) * 1996-04-10 2002-10-31 Gyula Hadlaczky Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes
US6025155A (en) * 1996-04-10 2000-02-15 Chromos Molecular Systems, Inc. Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes
WO1998008379A1 (en) 1996-08-27 1998-03-05 Dana-Farber Cancer Institute Methods for identifying modulators of cellular interactions mediated by osteopontin
US6150162A (en) * 1998-12-17 2000-11-21 Isis Pharmaceuticals Inc. Antisense modulation of CD44 expression
AU3149200A (en) 1999-01-18 2000-08-01 Osteometer Biotech As Genetic predisposition
CA2370301A1 (en) * 1999-04-15 2000-10-26 Children's Medical Center Corporation Osteopontin-derived chemotactic and inhibitory agents and uses therefor
AU4256901A (en) 2000-03-23 2001-10-03 Glaxo Group Limited Method of screening for inhibitors of osteopontin
BR0213078A (pt) * 2001-09-25 2004-11-23 Fujisawa Pharmaceutical Co Anticorpo recombinante anti-osteopontina e uso do mesmo
CA2373854A1 (en) * 2002-02-28 2003-08-28 Alain Moreau Methods of diagnosing and counteracting adolescent idiopathic scoliosis
EP1532268A4 (en) * 2002-03-21 2006-07-05 Yissum Res Dev Co PERIPHERAL BLOOD CELL MARKERS SUITABLE FOR THE DIAGNOSIS OF MULTIPLE SCLEROSIS AND THESE USEFUL METHODS AND KITS
WO2004024750A2 (en) * 2002-09-13 2004-03-25 Dyax Corporation Cd44-binding ligands
US20050282163A1 (en) * 2003-02-03 2005-12-22 Medstar Research Institute Washington Hospital Center Polymorphisms in elastin, fibrillin and related genes as predisposing to restenosis and to a therosclerosis
US20090104620A1 (en) * 2007-07-03 2009-04-23 Axial Biotech, Inc. Simplified Method of Determining Predisposition to Scoliosis

Similar Documents

Publication Publication Date Title
JP2010522699A5 (show.php)
Balzar et al. Increased TGF-β2 in severe asthma with eosinophilia
Bethea et al. Beta 2-microglobulin: its significance and clinical usefulness
WO2010038974A3 (ko) 이뮤노글로블린 에이 신증과 티지비엠 신증의 진단용 조성물 및 키트
Qian et al. Increased IL-23 and IL-17 expression by peripheral blood cells of patients with primary biliary cirrhosis
US20150355180A1 (en) Differential Expression of Novel Protein Markers for the Diagnosis and Treatment of Eosinophilic Esophagitis
RU2014118584A (ru) Композиции и способы лечения сердечной недостаточности
JP2010516678A5 (show.php)
WO2009132058A3 (en) Levels of bcma protein expression on b cells and use in diagnostic methods
JP2012237760A (ja) リスク階層化におけるプロカルシトニン(pct)の使用、及び原発性の非感染性疾患を有する患者の予後診断
JP2012509477A5 (show.php)
MX2013001327A (es) Uso de hmgb1 como marcador biologico de afecciones intestinales inflamatorias, metodo no invasivo para su deteccion en muestras fecales y kit para su realizacion.
RU2019106324A (ru) Гистоны и/или proadm в качестве маркеров, свидетельствующих о неблагоприятном событии
Stanescu et al. Salivary biomarkers of inflammation in systemic lupus erythematosus
Lien et al. Associations among systemic blood pressure, microalbuminuria and albuminuria in dogs affected with pituitary-and adrenal-dependent hyperadrenocorticism
Yuan et al. High expression of interleukin-33/ST2 predicts the progression and poor prognosis in chronic hepatitis B patients with hepatic flare
RU2008116567A (ru) Биомаркеры
Banaszak et al. Endothelin-1 (ET-1), N-terminal fragment of pro-atrial natriuretic peptide (NTpro-ANP), and tumour necrosis factor alpha (TNF-α) in children with primary hypertension and hypertension of renal origin
JP2012526543A5 (show.php)
Li et al. Thyrotropin receptor antibody: A novel risk indicator for pregnancy loss
Magnussen et al. Safety and tolerability of an oral MMP-9 and-12 inhibitor, AZD1236, in patients with moderate-to-severe COPD: a randomised controlled 6-week trial
Zyguła et al. Is the leptin/BMI ratio a reliable biomarker for endometriosis?
Hanibuchi et al. Clinical significance of fractional exhaled nitric oxide and periostin as potential markers to assess therapeutic efficacy in patients with cough variant asthma
JP6934013B2 (ja) 糖尿病性腎症の早期病態の特異的な診断を可能とする検査方法
Kikuchi et al. Urinary and circulating levels of the anti-angiogenic isoform of vascular endothelial growth factor-A in patients with chronic kidney disease